Author contributions
F Schreeck, G Ahne, R Tremmel, E Schaeffeler and M Schwab made substantial contributions to the conception or design of the work, drafted/revised the work, gave final approval of the version to be published and agreed to be accountable for all aspects of the work.
Financial & competing interests disclosure
F Schreeck, R Tremmel, E Schaeffeler and M Schwab are supported by Robert Bosch Stiftung, Stuttgart, Germany. M Schwab and G Ahne are supported by the conect4children (c4c) project funded from the Innovative Medicines Initiative (IMI) 2 Joint Undertaking under grant agreement no. 777389. M Schwab has received research grants outside the submitted work from Green Cross WellBeing Co. Ltd, Gilead Sciences Inc., Agena Bioscience GmbH, Corat Therapeutics GmbH, CED Service GmbH and Robert Bosch GmbH, and has received honoraria for oral presentations at academically organized congresses and meetings. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.